Comparison of Clinical Trial Results of the Recently Approved
Immunotherapeutic Drugs for Advanced Biliary Tract Cancers

Samayita      Das
doi:10.2174/0115748871276666240123043710
Abstract

The recently approved immunotherapeutic drugs are Keytruda (pembrolizumab) and Imfinzi (durvalumab) for advanced biliary tract cancers that inhibit PD-1 receptor and PD-L1 ligand, respectively. In this perspective, the results of the two clinical trials, i.e., TOPAZ-1 (NCT03875235) and KEYNOTE-966 (NCT04003636), are critically appraised, compared, and discussed to assess the benefits of these two drugs in the context of the treatment of advanced biliary tract cancers with a focus on PD-L1 status and MIS (microsatellite instability) status and therapy responsiveness in the subgroups. Analyzing the PD-L2 status in biliary tract cancer patients can aid in assessing the prognostic value of PD-L2 expression in determining the clinical response and this may aid in appropriate patient stratification.
Keywords: PD-L1, PD-L2, PD-1, MIS, keytruda, imfinzi.
« Previous
Graphical Abstract

[1]
Oneda E, Abu Hilal M, Zaniboni A. Biliary tract cancer: Current medical treatment strategies. Cancers  2020; 12(5): 1237.
 [http://dx.doi.org/10.3390/cancers12051237] [PMID:  32423017]

[2]
Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol  2020; 11(4): 770-89.
 [http://dx.doi.org/10.21037/jgo-20-203] [PMID:  32953160]

[3]
Tam VC, Ramjeesingh R, Burkes R, Yoshida EM, Doucette S, Lim HJ. Emerging systemic therapies in advanced unresectable biliary tract cancer: Review and canadian perspective. Curr Oncol  2022; 29(10): 7072-85.
 [http://dx.doi.org/10.3390/curroncol29100555] [PMID:  36290832]

[4]
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res  2020; 10(3): 727-42.
 [PMID:  32266087]

[5]
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood  2009; 114(8): 1537-44.
 [http://dx.doi.org/10.1182/blood-2008-12-195792] [PMID:  19423728]

[6]
Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci  2003; 100(9): 5336-41.
 [http://dx.doi.org/10.1073/pnas.0931259100] [PMID:  12697896]

[7]
Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol  2007; 8(3): 239-45.
 [http://dx.doi.org/10.1038/ni1443] [PMID:  17304234]

[8]
Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med  2016; 375(18): 1767-78.
 [http://dx.doi.org/10.1056/NEJMra1514296] [PMID:  27806234]

[9]
Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol  2022; 19(5): 287-305.
 [http://dx.doi.org/10.1038/s41571-022-00601-9] [PMID:  35132224]

[10]
Wang Y, Du J, Gao Z, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer  2023; 128(7): 1196-207.
 [http://dx.doi.org/10.1038/s41416-022-02084-y] [PMID:  36522474]

[11]
Yaman Suleiman DC. Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma. J Clin Oncol  2015; 33(3) (3 suppl): 294.
 [http://dx.doi.org/10.1200/jco.2015.333]

[12]
Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res  2016; 22(2): 470-8.
 [http://dx.doi.org/10.1158/1078-0432.CCR-15-0715] [PMID:  26373575]

[13]
Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget  2017; 8(15): 24644-51.
 [http://dx.doi.org/10.18632/oncotarget.15602] [PMID:  28445951]

[14]
Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: Implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol  2016; 23(8): 2610-7.
 [http://dx.doi.org/10.1245/s10434-016-5101-y] [PMID:  27012989]

[15]
Jakubowski CD, Azad NS. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). Chin Clin Oncol  2020; 9(1): 2.
 [http://dx.doi.org/10.21037/cco.2019.12.10] [PMID:  32008328]

[16]
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol  2001; 2(3): 261-8.
 [http://dx.doi.org/10.1038/85330] [PMID:  11224527]

[17]
Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD‐L2 down‐regulates CD8 + T cell activation and cytolysis. Eur J Immunol  2003; 33(11): 3117-26.
 [http://dx.doi.org/10.1002/eji.200324270] [PMID:  14579280]

[18]
Yearley JH, Gibson C, Yu N, et al. PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer. Clin Cancer Res  2017; 23(12): 3158-67.
 [http://dx.doi.org/10.1158/1078-0432.CCR-16-1761] [PMID:  28619999]

[19]
Lesterhuis WJ, Punt CJA, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest  2011; 121(8): 3100-8.
 [http://dx.doi.org/10.1172/JCI43656] [PMID:  21765211]

[20]
Lesterhuis WJ, Steer H, Lake RA. PD-L2 is predominantly expressed by Th2 cells. Mol Immunol  2011; 49(1-2): 1-3.
 [http://dx.doi.org/10.1016/j.molimm.2011.09.014] [PMID:  22000002]

[21]
Messal N, Serriari NE, Pastor S, Nunès JA, Olive D. PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol  2011; 48(15-16): 2214-9.
 [http://dx.doi.org/10.1016/j.molimm.2011.06.436] [PMID:  21752471]

[22]
Matsubara T, Takada K, Azuma K, et al. A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol  2019; 26(6): 1925-33.
 [http://dx.doi.org/10.1245/s10434-019-07257-3] [PMID:  30815803]

[23]
Nakayama Y, Mimura K, Kua LF, et al. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer  2020; 23(6): 961-73.
 [http://dx.doi.org/10.1007/s10120-020-01079-z] [PMID:  32367440]

[24]
Jung HI, Jeong D, Ji S, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat  2017; 49(1): 246-54.
 [http://dx.doi.org/10.4143/crt.2016.066] [PMID:  27456947]

[25]
Shin SJ, Jeon YK, Kim PJ, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: Association with oncogenic proteins status. Ann Surg Oncol  2016; 23(2): 694-702.
 [http://dx.doi.org/10.1245/s10434-015-4903-7] [PMID:  26464193]

[26]
Zhang Y, Xu J, Hua J, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer  2019; 7(1): 233.
 [http://dx.doi.org/10.1186/s40425-019-0703-0] [PMID:  31464648]

[27]
Chervoneva I, Peck AR, Sun Y, et al. High PD-L2 predicts early recurrence of ER-positive breast cancer. JCO Precis Oncol  2023; 7(7): e2100498.
 [http://dx.doi.org/10.1200/PO.21.00498] [PMID:  36652667]

[28]
Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature  2017; 543(7645): 378-84.
 [http://dx.doi.org/10.1038/nature21386] [PMID:  28112728]

[29]
Heij L, Bednarsch J, Tan X, et al. Expression of checkpoint molecules in the tumor microenvironment of intrahepatic cholangiocarcinoma: Implications for immune checkpoint blockade therapy. Cells  2023; 12(6): 851.
 [http://dx.doi.org/10.3390/cells12060851] [PMID:  36980192]

[30]
Jeffrey S. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. J Clin Oncol  2015; 33(3)

[31]
Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS One  2014; 9(12): e115383.
 [http://dx.doi.org/10.1371/journal.pone.0115383] [PMID:  25536104]

[32]
Putra J, de Abreu FB, Peterson JD, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol  2015; 99(2): 240-4.
 [http://dx.doi.org/10.1016/j.yexmp.2015.07.005] [PMID:  26189129]

[33]
Mody K, Jain P, El-Refai SM, et al. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precis Oncol  2022; 6(6): e2100510.
 [http://dx.doi.org/10.1200/PO.21.00510] [PMID:  35675577]

[34]
Marcano-Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: Epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol  2016; 5(5): 61.
 [http://dx.doi.org/10.21037/cco.2016.10.09] [PMID:  27829275]

[35]
Tamai K, Nakamura M, Mizuma M, et al. Suppressive expression of CD 274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci  2014; 105(6): 667-74.
 [http://dx.doi.org/10.1111/cas.12406] [PMID:  24673799]

[36]
Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer  2018; 17(1): 129.
 [http://dx.doi.org/10.1186/s12943-018-0864-3] [PMID:  30139382]

[37]
Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: A meta-analysis of randomized clinical trials. ESMO Open  2021; 6(1): 100036.
 [http://dx.doi.org/10.1016/j.esmoop.2020.100036] [PMID:  33460964]

[38]
Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): A single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol  2022; 7(1): 38-48.
 [http://dx.doi.org/10.1016/S2468-1253(21)00348-4] [PMID:  34688374]

[39]
Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial. Lancet Oncol  2021; 22(5): 665-77.
 [http://dx.doi.org/10.1016/S1470-2045(21)00064-4] [PMID:  33812497]

[40]
Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol  2022; 23(5): 659-70.
 [http://dx.doi.org/10.1016/S1470-2045(22)00197-8] [PMID:  35427471]

[41]
Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: Toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol  2020; 55(1): 15-26.
 [http://dx.doi.org/10.1007/s00535-019-01620-7] [PMID:  31494725]

[42]
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science  2017; 357(6349): 409-13.
 [http://dx.doi.org/10.1126/science.aan6733] [PMID:  28596308]

[43]
Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol  2019; 12(1): 54.
 [http://dx.doi.org/10.1186/s13045-019-0738-1] [PMID:  31151482]

[44]
Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in advanced biliary tract cancers. Cancers  2021; 13(7): 1569.
 [http://dx.doi.org/10.3390/cancers13071569] [PMID:  33805461]

[45]
Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol  2019; 10(6): 1099-109.
 [http://dx.doi.org/10.21037/jgo.2019.08.08] [PMID:  31949927]

[46]
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med  2015; 372(26): 2509-20.
 [http://dx.doi.org/10.1056/NEJMoa1500596] [PMID:  26028255]

[47]
Le DT. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N Engl J Med  2022; 43(8): 1803-12.
 [http://dx.doi.org/10.1111/liv.15641]

[48]
Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet  2023; 401(10391): 1853-65.
 [http://dx.doi.org/10.1016/S0140-6736(23)00727-4] [PMID:  37075781]

[49]
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med  2010; 362(14): 1273-81.
 [http://dx.doi.org/10.1056/NEJMoa0908721] [PMID:  20375404]

[50]
Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401 ‐ MITSUBA). J Hepatobiliary Pancreat Sci  2023; 30(1): 102-10.
 [http://dx.doi.org/10.1002/jhbp.1219] [PMID:  35900311]

[51]
Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies. Int J Cancer  2020; 147(8): 2190-8.
 [http://dx.doi.org/10.1002/ijc.33013] [PMID:  32359091]

[52]
Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol  2020; 6(6): 888-94.
 [http://dx.doi.org/10.1001/jamaoncol.2020.0930] [PMID:  32352498]

[53]
de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: A review of preclinical and clinical evidence. Clin Cancer Res  2014; 20(21): 5384-91.
 [http://dx.doi.org/10.1158/1078-0432.CCR-14-1298] [PMID:  25204552]

[54]
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity  2013; 39(1): 74-88.
 [http://dx.doi.org/10.1016/j.immuni.2013.06.014] [PMID:  23890065]

[55]
Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis  2018; 5(3): 194-203.
 [http://dx.doi.org/10.1016/j.gendis.2018.05.003] [PMID:  30320184]

[56]
Solari JIG, Filippi-Chiela E, Pilar ES, et al. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells. BMC Cancer  2020; 20(1): 474.
 [http://dx.doi.org/10.1186/s12885-020-06964-5] [PMID:  32456685]

[57]
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science  2006; 313(5795): 1960-4.
 [http://dx.doi.org/10.1126/science.1129139] [PMID:  17008531]

[58]
Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer  2019; 18(1): 10.
 [http://dx.doi.org/10.1186/s12943-018-0928-4] [PMID:  30646912]

[59]
Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol  2021; 14(1): 10.
 [http://dx.doi.org/10.1186/s13045-020-01027-5] [PMID:  33413496]

[60]
Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E. Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? Transl Oncol  2020; 13(10): 100811.
 [http://dx.doi.org/10.1016/j.tranon.2020.100811] [PMID:  32622310]

[61]
Xue C, Zhu D, Chen L, et al. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. Transl Cancer Res  2019; 8(1): 111-9.
 [http://dx.doi.org/10.21037/tcr.2019.01.09] [PMID:  35116740]

[62]
Wang H, Yao H, Li C, et al. PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. OncoImmunology  2017; 6(7): e1327494.
 [http://dx.doi.org/10.1080/2162402X.2017.1327494] [PMID:  28811964]

[63]
Gao Y, Li S, Xu D, et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chin J Cancer  2017; 36(1): 61.
 [http://dx.doi.org/10.1186/s40880-017-0226-3] [PMID:  28754154]

[64]
Tanaka K, Miyata H, Sugimura K, et al. Negative influence of programmed death‐1‐ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci  2016; 107(6): 726-33.
 [http://dx.doi.org/10.1111/cas.12938] [PMID:  27015293]

[65]
Takamori S, Takada K, Azuma K, et al. Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients. Ann Surg Oncol  2019; 26(6): 1916-24.
 [http://dx.doi.org/10.1245/s10434-019-07231-z] [PMID:  30815801]

[66]
Wang Z, Li G, Wang Q, et al. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. OncoImmunology  2019; 8(2): e1541535.
 [http://dx.doi.org/10.1080/2162402X.2018.1541535] [PMID:  30713802]

[67]
Shin SJ, Jeon YK, Cho YM, et al. The association between PD-L1 expression and the clinical outcomes to vascular endothelial growth factor-targeted therapy in patients with metastatic clear cell renal cell carcinoma. Oncologist  2015; 20(11): 1253-60.
 [http://dx.doi.org/10.1634/theoncologist.2015-0151] [PMID:  26424759]

[68]
Baptista MZ, Sarian LO, Derchain SFM, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol  2016; 47(1): 78-84.
 [http://dx.doi.org/10.1016/j.humpath.2015.09.006] [PMID:  26541326]

[69]
Derks S, Nason KS, Liao X, et al. Epithelial PD-L2 expression marks barrett’s esophagus and esophageal adenocarcinoma. Cancer Immunol Res  2015; 3(10): 1123-9.
 [http://dx.doi.org/10.1158/2326-6066.CIR-15-0046] [PMID:  26081225]

[70]
Oh CR, Kim JE, Hong YS, et al. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability‐high/mismatch repair‐deficient orPOLE ‐mutated metastatic or unresectable colorectal cancer. Int J Cancer  2022; 150(12): 2038-45.
 [http://dx.doi.org/10.1002/ijc.33966] [PMID:  35179785]
Rights & Permissions Print Cite
Article Metrics
23
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0115748871276666240123043710	Print ISSN 1574-8871
Publisher Name Bentham Science Publisher	Online ISSN 1876-1038
Reviews on Recent Clinical Trials

Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
